Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — Investor Presentation (February 2024)
21 slides from Cellbxhealth's investor presentation, Feb 6, 2024
Slide 1: Transforming cancer care with the first FDA cleared medical device
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumor cells Andrew Newland and Ian Griffiths Shares Investor Event 6 February 2024
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Creating a new future for personalised cancer care
Creating a new future for personalised cancer care • FDA product clearance followed by – product sales growing and distributor network building – breakthrough data achieved for combined DNA analysis – large pharma customer secured and repeat business from biopharma • Building in 2024 towards – wider
Slide 4: ANGLE – Transforming cancer care
ANGLE – Transforming cancer care Parsortix® instrument Our Mission: Enable personalised cancer care with a simple blood test to guide treatment, INTENDED USE improving patient outcomes and The Parsortix® PC1 system is an in vitro diagnostic device reducing healthcare expenditure intended to enrich c
Slide 5: Near term commercial milestones
Near term commercial milestones • Building services revenues – Eisai secured as first large pharma customer. Other contract discussions in progress – Roll out of new assays (PD-L1, DDR, HER2 and DNA molecular) • Building product revenues – Portrait+ product kit launched alongside instruments and cas
Slide 6: Parsortix system could address flaws in standard of care
Parsortix system could address flaws in standard of care • NCCN Guidelines recommend biopsies for all metastatic breast cancer patients (MBC) – tissue biopsies from the primary tumor are out-of-date – up-to-date information is needed to select treatment for personalised care – only samples a single
Slide 7: Parsortix system: capturing and harvesting living cancer cells
Parsortix system: capturing and harvesting living cancer cells Plan view Platform technology The Parsortix system harvests cancer cells from blood based on their larger size and lack of deformability. CTC clusters including large CTC clusters are preferentially captured Inlet Outlet Other cells can
Slide 8: Parsortix system patent protected worldwide
Parsortix® system patent protected worldwide • Stepped, microscale cell separators for fluid flow and cell separation • Manufactured under ISO 13485:2016 quality control • Scalable business with third-party manufacturers • 26 granted patents: United States, Europe, China, Australia, Canada, Japan, M
Slide 9: Animation showing operation of Parsortix cassette
Animation showing operation of Parsortix cassette © ANGLE plc 2024 9
Slide 10: Patient blood flowing in Parsortix cassette
Patient blood flowing in Parsortix cassette © ANGLE plc 2024 10
Slide 11: Products – international sales and distribution network
Products – international sales and distribution network • Continued expansion of commercial operations – sales, logistics, product management, service and maintenance • Direct sales team – US, UK, Ireland, Belgium and Netherlands • Distribution partners selected for other key territories based on: –
Slide 12: Services - differentiated pharma services offering
Services - differentiated pharma services offering • Customer base established and growing Key differentiators – multiple customers, repeat business – new customers in 2024 and growing pipeline • Repeat testing before, during and after treatment • Significant revenue and profitability potential • Ac
Slide 13: Services – example customers and active projects
Services – example customers and active projects Global Japanese pharma company • Revenues >£4 billion >10,000 employees • >80 active oncology clinical trials >60,000 participants • HER2 targeting antibody-drug conjugate (ADC) being co-developed by Eisai and Bliss Biopharmaceutical Co., Ltd as part
Slide 14: Content – 'Portrait+' product kit for distribution
Content – ‘Portrait+’ product kit for distribution Antibody kit for robust and consistent imaging by Parsortix customers includes: • Antibodies directly conjugated and mixed into a single vial: – Epithelial markers – Mesenchymal markers – Blood lineage markers • Lyophilised for shipping, storage and
Slide 15: Content – HER2 assay kit in collaboration with BioView
Content – HER2 assay kit in collaboration with BioView • Breast cancer is highly heterogeneous and HER2 status can change over time 80.2% • New antibody-drug conjugates (ADCs) to treat patients with low HER2 status predicted increase in global cases of breast cancer from 2020 to 2040 • Developing a
Slide 16: DNA sequencing of CTCs (living) and ctDNA (dead)
DNA sequencing of CTCs (living) and ctDNA (dead) © ANGLE plc 2024 16
Slide 17: Proof of concept on patient samples
Proof of concept on patient samples DNA NGS Assay High-multiplex Illumina NGS assay for DNA profiling CTC-DNA and ctDNA extracted from blood samples of 47 patients with Breast, Lung, Ovarian or Prostate Cancer and profiled by NGS Patients with variants Patients positive in Patients positive in found
Slide 18: CTC-DNA / ctDNA combined profiling: summary Illumina NGS
CTC-DNA / ctDNA combined profiling: summary Illumina NGS • Results from 47 cancer patients DNA variants found in CTCs with FDA cleared • High quality DNA in all samples drugs for the variants in tissue or plasma including • Actionable DNA variants found in CTCs not in • PIK3CA (E545K): Alpelisib (Pi
Slide 19: Strong body of evidence
Strong body of evidence • FDA clearance expected to help At 31 December 2023 Parsortix become the CTC system of choice Clinically actionable biomarkers including: 81 published in • Installed base of over 290 Parsortix systems in active use EGFR BRAF KRAS 57 high impact journals 41 publications indep
Slide 20: Near term commercial milestones
Near term commercial milestones • Building services revenues – Eisai secured as first large pharma customer. Other contract discussions in progress – Roll out of new assays (PD-L1, DDR, HER2 and DNA molecular) • Building product revenues – Portrait+ product kit launched alongside instruments and cas
Slide 21: Andrew Newland, CEO and Ian Griffiths, CFO contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom www.angleplc.com Andrew Newland, CEO andrew.newland@angleplc.com Ian Griffiths, CFO i.griffiths@angleplc.com 21